This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
7 Leveraged ETFs Rallying on Moderna's Coronavirus Vaccine News
by Sweta Jaiswal, FRM
Here we highlight some leveraged ETFs that were up more than 7% on the favorable update from Moderna's vaccine progress.
6 Best-Performing Leveraged ETF Areas of Last Week
by Sanghamitra Saha
Last week was all about vaccine hopes and a stupendous Wall Street rally.
Leveraged ETF Areas That Gained the Most on Vaccine Hopes
by Sanghamitra Saha
Wall Street spiked on Nov 9 on news that a Pfizer and BioNTech vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial.
5 Top-Performing Leveraged ETFs of Last Week
by Sanghamitra Saha
The S&P 500, the Dow Jones and the Nasdaq Composite lost about 0.5%, 1% and 1.1%, respectively, in the past week.
Leveraged ETFs That Are Riding High on a Solid Market Rally
by Sweta Killa
The solid run came on optimism surrounding the additional stimulus and a coronavirus vaccine push that has bolstered investors' confidence in the stock market.
5 Top-Performing Leveraged ETFs of Last Week
by Sanghamitra Saha
Wall Street was upbeat last week with the S&P 500, the Dow Jones and the Nasdaq gaining about 3.3%, 2.6% and 3.4%, respectively. These leveraged ETFs were the top-performers last week.
6 Top-Performing Leveraged ETFs of Last Week
by Sanghamitra Saha
Wall Street put up a feeble show last week with the S&P 500, the Dow Jones and the Nasdaq Composite adding about 0.64%, 1.8% and 0.08%, respectively.
5 High-Flying Leveraged ETFs of Last Week
by Sweta Killa
The U.S. stock market extended its bull rally to start the month of June with surprisingly upbeat job data.
10 Top-Performing Leveraged ETFs of May
by Sweta Killa
The easing of lockdown measures is propelling demand, leading to renewed confidence among investors.
Leveraged ETFs That More Than Doubled in April
by Sweta Killa
U.S. stocks came back roaring in April buoyed by unprecedented fiscal and monetary stimulus, progress in the development of a coronavirus vaccine or treatment as well as optimism over the reopening of the economy.